Affibody Molecules as Targeting Vectors for PET Imaging; Cancers; Vol. 12, iss. 3
| Parent link: | Cancers Vol. 12, iss. 3.— 2020.— [651, 21 p.] |
|---|---|
| Main Author: | |
| Corporate Author: | |
| Other Authors: | |
| Summary: | Title screen Affibody molecules are small (58 amino acids) engineered scaffold proteins that can be selected to bind to a large variety of proteins with a high affinity. Their small size and high affinity make them attractive as targeting vectors for molecular imaging. High-affinity affibody binders have been selected for several cancer-associated molecular targets. Preclinical studies have shown that radiolabeled affibody molecules can provide highly specific and sensitive imaging on the day of injection; however, for a few targets, imaging on the next day further increased the imaging sensitivity. A phase I/II clinical trial showed that 68Ga-labeled affibody molecules permit an accurate and specific measurement of HER2 expression in breast cancer metastases. This paper provides an overview of the factors influencing the biodistribution and targeting properties of affibody molecules and the chemistry of their labeling using positron emitters. |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://doi.org/10.3390/cancers12030651 |
| Format: | Electronic Book Chapter |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664970 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 664970 | ||
| 005 | 20251114161728.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\36155 | ||
| 090 | |a 664970 | ||
| 100 | |a 20210607d2020 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Affibody Molecules as Targeting Vectors for PET Imaging |f V. M. Tolmachev, A. M. Orlova | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: 118 tit.] | ||
| 330 | |a Affibody molecules are small (58 amino acids) engineered scaffold proteins that can be selected to bind to a large variety of proteins with a high affinity. Their small size and high affinity make them attractive as targeting vectors for molecular imaging. High-affinity affibody binders have been selected for several cancer-associated molecular targets. Preclinical studies have shown that radiolabeled affibody molecules can provide highly specific and sensitive imaging on the day of injection; however, for a few targets, imaging on the next day further increased the imaging sensitivity. A phase I/II clinical trial showed that 68Ga-labeled affibody molecules permit an accurate and specific measurement of HER2 expression in breast cancer metastases. This paper provides an overview of the factors influencing the biodistribution and targeting properties of affibody molecules and the chemistry of their labeling using positron emitters. | ||
| 461 | |t Cancers | ||
| 463 | |t Vol. 12, iss. 3 |v [651, 21 p.] |d 2020 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a PET | |
| 610 | 1 | |a affibody molecules | |
| 610 | 1 | |a HER2 | |
| 610 | 1 | |a EGFR | |
| 610 | 1 | |a molecular imaging | |
| 610 | 1 | |a radiolabeling | |
| 700 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |3 (RuTPU)RU\TPU\pers\46552 |9 22210 | |
| 701 | 1 | |a Orlova |b A. M. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1960- |g Anna Markovna |3 (RuTPU)RU\TPU\pers\46554 |9 22212 | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет |b Исследовательская школа химических и биомедицинских технологий |b Научно-исследовательский центр "Онкотераностика" |3 (RuTPU)RU\TPU\col\27561 |
| 801 | 2 | |a RU |b 63413507 |c 20210607 |g RCR | |
| 856 | 4 | |u https://doi.org/10.3390/cancers12030651 | |
| 942 | |c CF | ||